ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
07 Apr, 2025
Lexeo Therapeutics announced encouraging interim results from its Phase 1/2 trials of LX2006 for treating Friedreich ataxia (FA) cardiomyopathy. Data from the SUNRISE-FA and Weill Cornell Medicine trials showed clinically meaningful improvements in cardiac biomarkers and function, along with increased frataxin expression in all patients with cardiac biopsies.
LX2006 was generally well tolerated, with no serious adverse events. Over 80% of participants with abnormal baseline heart function showed significant improvements, including normalization of left ventricular mass index (LVMI) and reductions in troponin I levels.
Lexeo plans to launch a registrational trial by early 2026, following alignment with the FDA on key study endpoints, and expects to begin a supporting natural history study in mid-2025.